Sign in
PHIOW Stock Price, Chart, Stats & News
Phio Pharmaceuticals Corp.
Save
Phio Pharmaceuticals Corp. (PHIOW) does not currently pay a dividend.
421,414
Market cap
–
Current P/E
–
Forward P/E
PHIOW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -40.48% |
ROE | -66.59% |
D/E | – |
Interest coverage ratio | – |
PHIOW valuation
P/E | – |
P/S | – |
P/B | 0.73x |
P/CF | -1.83x |
P/FCF | -1.83x |
P/OCF | -1.83x |
PEG | -4065.79x |
EV multiple | -3.96x |
About
Established in 2011 and headquartered in Marlborough, Massachusetts, Phio Pharmaceuticals Corp. is a biotechnology firm dedicated to advancing immuno-oncology treatments within the United States. Central to its approach is the proprietary INTASYL therapeutic platform, engineered to counteract the mechanisms by which tumors evade or suppress the body's natural immune response. Its pipeline features several promising candidates: PH-762 is designed to inhibit the PD-1 checkpoint protein found on immune cells, with development focused on applications in adoptive cell transfer (ACT).
Similar securities
Based on sector and market capitalization
Report issue